Gary Nachman
Stock Analyst at Raymond James
(3.83)
# 670
Out of 5,090 analysts
97
Total ratings
58.9%
Success rate
7.28%
Average return
Main Sectors:
Stocks Rated by Gary Nachman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Reiterates: Strong Buy | $85 → $89 | $81.68 | +8.96% | 4 | Oct 30, 2025 | |
| BLCO Bausch + Lomb | Reiterates: Outperform | $18 → $19 | $16.82 | +12.96% | 2 | Oct 30, 2025 | |
| LENZ LENZ Therapeutics | Reiterates: Outperform | $40 → $50 | $26.72 | +87.13% | 3 | Oct 20, 2025 | |
| ABBV AbbVie | Reiterates: Outperform | $236 → $250 | $226.08 | +10.58% | 17 | Oct 17, 2025 | |
| AMGN Amgen | Assumes: Market Perform | n/a | $329.89 | - | 2 | Sep 3, 2025 | |
| VERU Veru Inc. | Maintains: Outperform | $30 → $20 | $2.49 | +703.21% | 2 | Aug 13, 2025 | |
| SDGR Schrödinger | Maintains: Outperform | $25 → $28 | $17.64 | +58.73% | 5 | Nov 13, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $275 → $298 | $458.12 | -34.95% | 7 | Nov 1, 2024 | |
| ACHV Achieve Life Sciences | Initiates: Strong Buy | $20 | $4.62 | +332.90% | 1 | Sep 27, 2024 | |
| PCRX Pacira BioSciences | Maintains: Outperform | $41 → $37 | $23.99 | +54.23% | 13 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Strong Buy | $30 | $45.02 | -33.36% | 5 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $6.38 | +9.72% | 1 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $169.70 | - | 11 | Sep 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $5 → $4 | $12.18 | -67.16% | 5 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $35 → $30 | $14.58 | +105.76% | 4 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $32 | $3.56 | +798.88% | 1 | Feb 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $16 → $14 | $10.93 | +28.09% | 2 | Feb 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $11 → $10 | $28.46 | -64.86% | 1 | Nov 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $30 | $48.92 | -38.68% | 2 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $810 → $750 | $3.97 | +18,791.69% | 2 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $15 → $8 | $6.93 | +15.44% | 2 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $20 → $21 | $26.77 | -21.55% | 5 | May 11, 2020 |
Ionis Pharmaceuticals
Oct 30, 2025
Reiterates: Strong Buy
Price Target: $85 → $89
Current: $81.68
Upside: +8.96%
Bausch + Lomb
Oct 30, 2025
Reiterates: Outperform
Price Target: $18 → $19
Current: $16.82
Upside: +12.96%
LENZ Therapeutics
Oct 20, 2025
Reiterates: Outperform
Price Target: $40 → $50
Current: $26.72
Upside: +87.13%
AbbVie
Oct 17, 2025
Reiterates: Outperform
Price Target: $236 → $250
Current: $226.08
Upside: +10.58%
Amgen
Sep 3, 2025
Assumes: Market Perform
Price Target: n/a
Current: $329.89
Upside: -
Veru Inc.
Aug 13, 2025
Maintains: Outperform
Price Target: $30 → $20
Current: $2.49
Upside: +703.21%
Schrödinger
Nov 13, 2024
Maintains: Outperform
Price Target: $25 → $28
Current: $17.64
Upside: +58.73%
Alnylam Pharmaceuticals
Nov 1, 2024
Maintains: Outperform
Price Target: $275 → $298
Current: $458.12
Upside: -34.95%
Achieve Life Sciences
Sep 27, 2024
Initiates: Strong Buy
Price Target: $20
Current: $4.62
Upside: +332.90%
Pacira BioSciences
Jul 31, 2024
Maintains: Outperform
Price Target: $41 → $37
Current: $23.99
Upside: +54.23%
Mar 28, 2024
Initiates: Strong Buy
Price Target: $30
Current: $45.02
Upside: -33.36%
Mar 28, 2024
Initiates: Outperform
Price Target: $7
Current: $6.38
Upside: +9.72%
Sep 29, 2023
Initiates: Market Perform
Price Target: n/a
Current: $169.70
Upside: -
Mar 3, 2023
Maintains: Market Perform
Price Target: $5 → $4
Current: $12.18
Upside: -67.16%
Mar 1, 2023
Maintains: Outperform
Price Target: $35 → $30
Current: $14.58
Upside: +105.76%
Feb 22, 2023
Maintains: Outperform
Price Target: $40 → $32
Current: $3.56
Upside: +798.88%
Feb 17, 2023
Downgrades: Market Perform
Price Target: $16 → $14
Current: $10.93
Upside: +28.09%
Nov 7, 2022
Maintains: Market Perform
Price Target: $11 → $10
Current: $28.46
Upside: -64.86%
Nov 4, 2022
Maintains: Outperform
Price Target: $40 → $30
Current: $48.92
Upside: -38.68%
Aug 11, 2022
Maintains: Outperform
Price Target: $810 → $750
Current: $3.97
Upside: +18,791.69%
Aug 10, 2022
Maintains: Market Perform
Price Target: $15 → $8
Current: $6.93
Upside: +15.44%
May 11, 2020
Maintains: Market Perform
Price Target: $20 → $21
Current: $26.77
Upside: -21.55%